Please wait a minute...
ZJUS-B
Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology)  2017, Vol. 18 Issue (1): 15-26    DOI: 10.1631/jzus.B1600303
Reviews     
Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice
Ming Zhao, Xian-feng Ding, Jian-yu Shen, Xi-ping Zhang, Xiao-wen Ding, Bin Xu
College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou 310018, China; Department of Tumor Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, China; Institute of Occupational Diseases, Zhejiang Academy of Medical Sciences, Hangzhou 310013, China
Download:     PDF (0 KB)     
Export: BibTeX | EndNote (RIS)      

Abstract  Breast cancer is one of the malignant tumors with the highest morbidity and mortality. It is helpful to reduce the rate of tumor recurrence and metastasis by treating breast cancer with adjuvant chemotherapy, so as to increase the cure rate or survival of patients. In recent years, liposomes have been regarded as a kind of new carrier for targeted drugs. Being effective for enhancing drug efficacy and reducing side effects, they have been widely used for developing anticancer drugs. As a kind of anthracycline with high anticancer activity, doxorubicin can treat or alleviate a variety of malignant tumors effectively when it is used on its own or in combination with other anticancer drugs. Although liposomal doxorubicin has been extensively used in the adjuvant chemotherapy of breast cancer, its exact therapeutic efficacy and side effects have not been definitely proven. Various clinical studies have adopted different combined regimes, dosages, and staging, so their findings differ to certain extent. This paper reviews the clinical application of liposomal doxorubicin in the adjuvant chemotherapy of breast cancer and illustrates therapeutic effects and side effects of pegylated liposomal doxorubicin (PLD) and non-PLD (NPLD) in clinical research, in order to discuss the strategies for applying these drugs in such adjuvant chemotherapy, looking forward to providing references for related research and clinical treatment in terms of dosage, staging, combined regimes, and analysis methods and so on.

Key words： Liposomal doxorubicin      Toxic and side effects      Breast cancer      Adjuvant chemotherapy      Therapeutic effect      Toxic and side effects     
Received: 10 August 2016      Published: 03 January 2017
CLC:  R979.1+4  
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
Ming Zhao
Xian-feng Ding
Jian-yu Shen
Xi-ping Zhang
Xiao-wen Ding
Bin Xu
Cite this article:

Ming Zhao, Xian-feng Ding, Jian-yu Shen, Xi-ping Zhang, Xiao-wen Ding, Bin Xu. Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2017, 18(1): 15-26.

URL:

http://www.zjujournals.com/xueshu/zjus-b/10.1631/jzus.B1600303     OR     http://www.zjujournals.com/xueshu/zjus-b/Y2017/V18/I1/15

[1] Shi-chong Liao, Jin-xin Li, Li Yu, Sheng-rong Sun. Protein tyrosine phosphatase 1B expression contributes to the development of breast cancer[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2017, 18(4): 334-342.
[2] Shu-min Liu, Shi-yi Ou, Hui-hua Huang. Green tea polyphenols induce cell death in breast cancer MCF-7 cells through induction of cell cycle arrest and mitochondrial-mediated apoptosis[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2017, 18(2): 89-98.
[3] Chun-xi Wang, Shu-li Guo, Li-na Han. Successful treatment of accessory breast cancer with endocrine therapy[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2017, 18(1): 70-75.
[4] Zhao-ji Liu, Gregg L. Semenza, Hua-feng Zhang. Hypoxia-inducible factor 1 and breast cancer metastasis[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2015, 16(1): 32-43.
[5] Xinguo Jiang. Macrophage-produced IL-10 limits the chemotherapy efficacy in breast cancer[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2015, 16(1): 44-45.
[6] Hui-xin Liu, Xiao-li Li, Chen-fang Dong. Epigenetic and metabolic regulation of breast cancer stem cells[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2015, 16(1): 10-17.
[7] Wei Wang, Yun-ping Luo. MicroRNAs in breast cancer: oncogene and tumor suppressors with clinical potential[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2015, 16(1): 18-31.
[8] Xinguo Jiang. Harnessing the immune system for the treatment of breast cancer[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2014, 15(1): 1-15.
[9] Sheereen Tarannum, Zarina Arif, Khursheed Alam. Binding of circulating autoantibodies in breast cancer to native and peroxynitrite-modified RNA[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2013, 14(1): 40-46.
[10] Lin-run Wang, Guo-bing Zhang, Jian Chen, Jun Li, Ming-wei Li, Nong Xu, Yang Wang, Jian-zhong Shentu. RRM1 gene expression in peripheral blood is predictive of shorter survival in Chinese patients with advanced non-small-cell lung cancer treated by gemcitabine and platinum[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2011, 12(3): 174-179.
[11] Yi ZHENG, Jing ZHANG, Zhen-zhen XU,Jian-ming SHENG, Xiao-chen ZHANG, Hao-hao WANG, Xiao-dong TENG, Xiao-jiao LIU, Jiang CAO, Li-song TENG. Quantitative profiles of the mRNAs of ER-α and its novel variant ER-α36 in breast cancers and matched normal tissues[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2010, 11(2): 144-150.
[12] Ching-hung LIN, Huang-chun LIEN, Fu-chang HU, Yen-shen LU, Sung-hsin KUO, Ling-chu WU, San-lin YOU, Ann-lii CHENG, King-jen CHANG, Chiun-sheng HUANG. Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapy[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2010, 11(1): 1-9.
[13] Shan-zhi GU, Xin-han ZHAO, Ling-xiao ZHANG, Li LI, Zhi-yu WANG, Min MENG, Gai-li AN. Anti-angiogenesis effect of generation 4 polyamidoamine/vascular endothelial growth factor antisense oligodeoxynucleotide on breast cancer in vitro[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2009, 10(3): 159-167.
[14] Li-song TENG, Yi ZHENG, Hao-hao WANG. BRCA1/2 associated hereditary breast cancer[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2008, 9(2): 85-89.
[15] Jin ZHANG, Yan LIU. HER2 over-expression and response to different chemotherapy regimens in breast cancer[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2008, 9(1): 5-9.